

# Lawrence S Lamb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1043317/publications.pdf>

Version: 2024-02-01

49  
papers

1,456  
citations

430874

18  
h-index

361022

35  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1901  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression. <i>Cancers</i> , 2022, 14, 2339.	3.7	17
2	Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched unrelated donor transplantation. <i>American Journal of Hematology</i> , 2021, 96, E396-E398.	4.1	4
3	A combined treatment regimen of MGMT-modified $\gamma\delta$ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. <i>Scientific Reports</i> , 2021, 11, 21133.	3.3	22
4	Therapeutic Potential of Cells of the Immune System. , 2020, , 41-67.		0
5	Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 233-238.	2.0	10
6	Clinical-scale manufacturing of $\gamma\delta$ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis. <i>Bone Marrow Transplantation</i> , 2018, 53, 766-769.	2.4	8
7	IMMU-15. ENGINEERED-DRUG RESISTANT GAMMA-DELTA ( $\gamma\delta$ ) T CELLS COMBINED WITH IMMUNE CHECKPOINT BLOCKADE AUGMENTED KILLING OF CANCER CELLS. <i>Neuro-Oncology</i> , 2018, 20, vi124-vi124.	1.2	0
8	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1345-1348.	2.4	4
9	Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. <i>Journal of Immunology Research</i> , 2016, 2016, 1-10.	2.2	14
10	In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0166891.	2.5	72
11	In vivo expansion and activation of $\gamma\delta$ T cells as immunotherapy for refractory neuroblastoma. <i>Medicine (United States)</i> , 2016, 95, e4909.	1.0	74
12	Favorable Immune Reconstitution Profile after Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 2236-2236.	1.4	1
13	Improved Outcomes Following Drug-Resistant Immunotherapy in a Human Xenograft Model of Temozolomide-Resistant Glioblastoma Multiforme. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S240.	2.0	0
14	The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 551-562.	4.2	18
15	Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. <i>Cell Reports</i> , 2015, 12, 1668-1677.	6.4	95
16	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1626-1635.	1.3	0
17	Dynamics of Circulating $\gamma\delta$ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma. <i>PLoS ONE</i> , 2015, 10, e0122387.	2.5	17
18	Recovery of CMV-Specific T Cells Following Alternative Donor Allogeneic Transplant with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2015, 126, 5462-5462.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Improving the safety of cell therapy products by suicide gene transfer. <i>Frontiers in Pharmacology</i> , 2014, 5, 254.	3.5	165
20	Cytotoxic and Regulatory Properties of Circulating VÎ1+ Î³Î T Cells: A New Player on the Cell Therapy Field?. <i>Molecular Therapy</i> , 2014, 22, 1416-1422.	8.2	93
21	Broad T-Cell Receptor Repertoire in T-Lymphocytes Derived from Human Induced Pluripotent Stem Cells. <i>PLoS ONE</i> , 2014, 9, e97335.	2.5	29
22	Abstract 643A: Characterization of the Î³Î T-cell response in high-grade glioma. , 2014, , .		0
23	Immune Reconstitution and Chimerism in Allogeneic HSCT Patients Treated with Post-HSCT High Dose Cyclophosphamide As Prophylaxis Against GvHD. <i>Blood</i> , 2014, 124, 2474-2474.	1.4	0
24	Persistence pays off for Î³Î T-cell therapies. <i>Cytotherapy</i> , 2013, 15, 397-398.	0.7	0
25	Engineered Drug Resistant Î³Î T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy. <i>PLoS ONE</i> , 2013, 8, e51805.	2.5	68
26	CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated VÎ1+ Î³Î T Cells. <i>PLoS ONE</i> , 2013, 8, e68729.	2.5	39
27	Abstract 530: Circulating Î³Î T cells are activated and depleted during progression of high-grade gliomas: Implications for Î³Î T cells therapy of GBM. , 2012, , .		0
28	Preclinical evaluation of ex vivo expanded/activated Î³Î T cells for immunotherapy of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 101, 179-188.	2.9	47
29	Glioma Cells Display Complex Cell Surface Topographies That Resist the Actions of Cytolytic Effector Lymphocytes. <i>Journal of Immunology</i> , 2010, 185, 4793-4803.	0.8	26
30	Abstract 1942: VÎ1+ Î³Î T cells are cytotoxic against glioblastoma multiforme. , 2010, , .		0
31	Characterization and immunotherapeutic potential of Î³Î T-cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2009, 11, 357-367.	1.2	69
32	Î³Î T cells as immune effectors against high-grade gliomas. <i>Immunologic Research</i> , 2009, 45, 85-95.	2.9	26
33	Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield.. <i>Blood</i> , 2007, 110, 3047-3047.	1.4	0
34	ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone.. <i>Blood</i> , 2007, 110, 5006-5006.	1.4	0
35	Characterization of the Î³Î T cell response to acute leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1072-1080.	4.2	50
36	Hematologic aspects of myeloablative therapy and bone marrow transplantation. <i>Journal of Clinical Laboratory Analysis</i> , 2005, 19, 47-79.	2.1	9

#	ARTICLE	IF	CITATIONS
37	T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2005, 65B, 37-41.	1.5	5
38	Î³Î´ T cells: A new frontier for immunotherapy?. Biology of Blood and Marrow Transplantation, 2005, 11, 161-168.	2.0	75
39	Efficacy of Therapeutic Group by Telephone for Women With Breast Cancer. Cancer Nursing, 2003, 26, 439-447.	1.5	37
40	Hematopoietic cellular therapy: implications for the flow cytometry laboratory. Hematology/Oncology Clinics of North America, 2002, 16, 455-476.	2.2	6
41	Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood, 2001, 98, 505-512.	1.4	132
42	Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. British Journal of Haematology, 2001, 114, 11-24.	2.5	54
43	Cryopreserved normal macrophages as a control for assays of macrophage function. In Vitro Cellular and Developmental Biology - Animal, 1999, 35, 64-66.	1.5	2
44	Rapid Communication: Increased Frequency of TCRÎ³Î´+ T Cells in Disease-Free Survivors Following T Cell-Depleted, Partially Mismatched, Related Donor Bone Marrow Transplantation for Leukemia. Stem Cells and Development, 1996, 5, 503-509.	1.0	132
45	Morphologic and Functional Characteristics of Alveolar Macrophages Following Cryopreservation. Cryobiology, 1995, 32, 344-357.	0.7	8
46	Effect of dietary copper on colonic tumor production and aortic integrity in the rat. Journal of Surgical Research, 1987, 42, 503-512.	1.6	14
47	Colorectal cancer in animal modelsâ€”A review. Journal of Surgical Research, 1987, 43, 476-487.	1.6	14
48	WHAT TO EXPECT WHEN YOUR PATIENT'S SCHEDULED FOR MITRAL VALVE REPLACEMENT. Nursing, 1985, 15, 58-67.	0.3	0
49	THINK YOU KNOW septic shock? Read this. Nursing, 1982, 12, 34-43.	0.3	0